VTVT – vtv therapeutics inc. - class a (US:NASDAQ)
Stock Stats
News
vTv Therapeutics Inc. (NASDAQ: VTVT) is now covered by analysts at Alliance Global Partners. They set a "buy" rating and a $35.00 price target on the stock.
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference [Yahoo! Finance]
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
Diabetes Pipeline Landscape Research Report 2024: Comprehensive Insights About 200+ Companies and 200+ Pipeline Drugs [Yahoo! Finance]
Form 4 vTv Therapeutics Inc. For: Mar 05 Filed by: AKKARAJU SRINIVAS
Form 4 vTv Therapeutics Inc. For: Mar 05 Filed by: Samsara BioCapital, L.P.
Form 4 vTv Therapeutics Inc. For: Nov 15 Filed by: SEKHRI PAUL J
Form 10-Q vTv Therapeutics Inc. For: Sep 30
Form 8-K vTv Therapeutics Inc. For: Nov 12
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.